Related Experiment Video
Updated: Oct 21, 2025
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Outcomes of salvage lung resections in advanced EGFR-mutant lung adenocarcinomas under EGFR TKIs
Ying-Yuan Chen1,2, Yi-Ting Yen1, Wu-Wei Lai1
1Division of Thoracic Surgery, Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan.
Background:
Studies regarding the outcomes of salvage lung resections of epidermal growth factor receptor (EGFR)-mutant advanced lung adenocarcinomas (ALAs) following treatment with EGFR tyrosine kinase inhibitors (TKIs) are limited, hence the objective of this study was to investigate such outcomes.
Methods:
A total of 29 patients with EGFR-mutant ALA who underwent salvage surgery after EGFR-TKI treatment from October 2013 through January 2019 were enrolled. The patients were divided into two groups according to the surgical indications. Their perioperative parameters and surgical outcomes, including progression-free survival (PFS) and overall survival (OS), were then analyzed.
Results:
The initial stages of the patients were stage IIIB (seven patients), IVA (17 patients), and IVB (five patients). Their surgical indications included residual tumor (25 patients) and progressive disease (PD) (four patients). They all underwent surgery via minimally invasive approaches and the median follow-up was 33.9 months. Within that follow-up duration, the median PFS after surgery was 36.4 months, and the median OS was still not reached. There were no significant differences in PFS or OS according to the different EGFR-TKIs used, the different durations of EGFR-TKI treatment before surgery, or the different surgical indications. However, the patients presenting with pleural seeding before EGFR-TKI treatment had significantly poorer PFS and OS than the other patients (P < 0.001).
Conclusions:
Salvage surgery following EGFR-TKI treatment of ALAs is a safe procedure with acceptable intra- and postoperative results. However, studies involving more cases and longer follow-up periods are needed to clarify its benefits.
Key Points:
Salvage surgery following EGFR-TKI treatment of ALAs is a safe procedure with acceptable intra- and postoperative results. Our results support the use of surgery following treatment with EGFR-TKIs such as afatinib in advanced lung cancer.
Insights
Salvage lung surgery after epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment for advanced lung adenocarcinoma is safe. However, patients with pleural seeding before treatment had worse survival outcomes.
Area of Science:
- Oncology
- Thoracic Surgery
- Molecular Targeted Therapy
Background:
- Limited studies exist on salvage lung resections for EGFR-mutant advanced lung adenocarcinomas (ALAs) post-EGFR tyrosine kinase inhibitor (TKI) treatment.
- Investigating outcomes of these specific patient populations is crucial for treatment optimization.
Purpose of the Study:
- To evaluate the outcomes of salvage lung resections in patients with EGFR-mutant ALAs after EGFR-TKI treatment.
- To analyze perioperative parameters and survival rates (progression-free survival and overall survival).
Main Methods:
- Retrospective analysis of 29 patients with EGFR-mutant ALA who underwent salvage surgery post-EGFR-TKI treatment (Oct 2013 - Jan 2019).
- Patients were grouped by surgical indications (residual tumor vs. progressive disease).
- Minimally invasive surgical approaches were used, with a median follow-up of 33.9 months.
Main Results:
- Median progression-free survival (PFS) post-surgery was 36.4 months; median overall survival (OS) was not reached.
- No significant differences in PFS or OS were observed based on EGFR-TKIs used, treatment duration, or surgical indications.
- Patients with pre-treatment pleural seeding showed significantly poorer PFS and OS (P < 0.001).
Conclusions:
- Salvage surgery following EGFR-TKI treatment for ALAs is a safe procedure with acceptable perioperative results.
- Further research with larger cohorts and longer follow-up is necessary to fully establish the benefits of this approach.
- Results support the use of surgery in advanced lung cancer patients treated with EGFR-TKIs.
